We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
Read MoreHide Full Article
Nurix Therapeutics (NRIX - Free Report) shares rose 8.7% on Wednesday after the company announced that Sanofi (SNY - Free Report) has in-licensed exclusive rights to an undisclosed Nurix program aimed at a previously untreatable transcription factor for autoimmune diseases. This undisclosed target plays a key role in regulating inflammation and is separate from the previously revealed STAT6 degrader program, signed between the companies in 2019. The stock is gaining further in the pre-market hours on Thursday.
Nurix and Sanofi first established a strategic collaboration in 2019 to develop and commercialize a portfolio of targeted protein degradation therapies for patients with complex diseases across various therapeutic areas. The partnership utilizes NRIX’s proprietary DEL-AI discovery platform to discover small molecules that promote the degradation of three initially designated drug targets. In 2021, Sanofi exercised its option to expand the number of targets from three to five.
The latest update further expands the collaboration agreement between Nurix and Sanofi, highlighting the strength of its DEL-AI platform.
Year to date, NRIX stock has plunged 39.6% against the industry’s 1.2% growth.
Image Source: Zacks Investment Research
Details of NRIX’s Updated Collaboration Deal With SNY
Nurix's proprietary DEL-AI platform has enabled the discovery of novel binders, leading to the development of both targeted protein degraders and stand-alone binders for a previously untreatable transcription factor. Per management, this key target plays a crucial role in regulating proinflammatory cytokines and inflammation in autoimmune diseases, highlighting the potential of targeted protein degradation as an innovative therapeutic approach.
Under the revised collaboration, Nurix will utilize its DEL-AI drug discovery platform to develop novel agents that leverage E3 ligases for targeted protein degradation. Sanofi holds the right to license drug candidates emerging from this research, while Nurix retains the option to co-develop and co-promote up to two future products in the United States after demonstrating clinical proof of concept in dosing, efficacy, and safety studies.
For programs where Nurix exercises this option, both companies will share U.S. profits and losses equally, with NRIX also earning royalties on ex-U.S. sales. If the company chooses not to co-develop a program, it will receive milestone payments and royalties based on global development and sales from SNY.
Nurix has received a license extension fee of $15 million from Sanofi. The company remains eligible for up to $465 million in potential development, regulatory, and commercial milestone payments per licensed program, along with royalties on future sales.
In the past 30 days, estimates for Bayer’s earnings per share have increased from $1.14 to $1.19 for 2025. During the same time, earnings per share have increased from $1.23 to $1.28 for 2026. Year to date, shares of Bayer have gained 19.5%.
BAYRY’s earnings matched estimates in two of the trailing three quarters while missing the same on the remaining occasion, the average negative surprise being 19.61%.
In the past 30 days, the estimate for Corcept Therapeutics’ 2025 earnings per share has increased from $1.84 to $1.87. The estimate for 2026 earnings per share has increased from $3.05 to $3.11. Year to date, shares of Corcept Therapeutics have gained 66.3%.
CORT’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 20.08%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
Nurix Therapeutics (NRIX - Free Report) shares rose 8.7% on Wednesday after the company announced that Sanofi (SNY - Free Report) has in-licensed exclusive rights to an undisclosed Nurix program aimed at a previously untreatable transcription factor for autoimmune diseases. This undisclosed target plays a key role in regulating inflammation and is separate from the previously revealed STAT6 degrader program, signed between the companies in 2019. The stock is gaining further in the pre-market hours on Thursday.
Nurix and Sanofi first established a strategic collaboration in 2019 to develop and commercialize a portfolio of targeted protein degradation therapies for patients with complex diseases across various therapeutic areas. The partnership utilizes NRIX’s proprietary DEL-AI discovery platform to discover small molecules that promote the degradation of three initially designated drug targets. In 2021, Sanofi exercised its option to expand the number of targets from three to five.
The latest update further expands the collaboration agreement between Nurix and Sanofi, highlighting the strength of its DEL-AI platform.
Year to date, NRIX stock has plunged 39.6% against the industry’s 1.2% growth.
Image Source: Zacks Investment Research
Details of NRIX’s Updated Collaboration Deal With SNY
Nurix's proprietary DEL-AI platform has enabled the discovery of novel binders, leading to the development of both targeted protein degraders and stand-alone binders for a previously untreatable transcription factor. Per management, this key target plays a crucial role in regulating proinflammatory cytokines and inflammation in autoimmune diseases, highlighting the potential of targeted protein degradation as an innovative therapeutic approach.
Under the revised collaboration, Nurix will utilize its DEL-AI drug discovery platform to develop novel agents that leverage E3 ligases for targeted protein degradation. Sanofi holds the right to license drug candidates emerging from this research, while Nurix retains the option to co-develop and co-promote up to two future products in the United States after demonstrating clinical proof of concept in dosing, efficacy, and safety studies.
For programs where Nurix exercises this option, both companies will share U.S. profits and losses equally, with NRIX also earning royalties on ex-U.S. sales. If the company chooses not to co-develop a program, it will receive milestone payments and royalties based on global development and sales from SNY.
Nurix has received a license extension fee of $15 million from Sanofi. The company remains eligible for up to $465 million in potential development, regulatory, and commercial milestone payments per licensed program, along with royalties on future sales.
Nurix Therapeutics, Inc. Price and Consensus
Nurix Therapeutics, Inc. price-consensus-chart | Nurix Therapeutics, Inc. Quote
NRIX’s Zacks Rank & Other Stocks to Consider
Nurix currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the sector are Bayer (BAYRY - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
In the past 30 days, estimates for Bayer’s earnings per share have increased from $1.14 to $1.19 for 2025. During the same time, earnings per share have increased from $1.23 to $1.28 for 2026. Year to date, shares of Bayer have gained 19.5%.
BAYRY’s earnings matched estimates in two of the trailing three quarters while missing the same on the remaining occasion, the average negative surprise being 19.61%.
In the past 30 days, the estimate for Corcept Therapeutics’ 2025 earnings per share has increased from $1.84 to $1.87. The estimate for 2026 earnings per share has increased from $3.05 to $3.11. Year to date, shares of Corcept Therapeutics have gained 66.3%.
CORT’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 20.08%.